HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FTC Enforcement Hangs Over Memory Product Firm After Overlooking NAD Review

This article was originally published in The Rose Sheet

Executive Summary

KNH Online did not respond to NAD's request for information supporting claims for its Adderin supplement, including the statement "clinically proven to sky-rocket concentration by 312%" and a customer testimonial that "it started working within minutes of taking it … I experienced a mental clarity that I’d never felt before."

You may also be interested in...

Cold Sore Ad Claims Review Poses Test For OTC Monograph Indications

Council of Better Business Bureaus forwards review of ad claims for Aubio Life Sciences' monograph cold sore treatment to US FDA and FTC, after firm rejected advice to discontinue certain claims. Initial challenge was brought by GSK, which markets an NDA cold sore product.

GAO Memory Supplement Review Recalls FDA's Regulatory Challenges

GAO recommends better cooperation between FDA and FTC and more public outreach are key to preventing consumers from believing noncompliant cognitive benefit claims for supplements.

Supplement Claims Targeting Elderly, Weight Conscious Top FTC Priorities

Dubious supplement ad claims that have driven FTC enforcement in the sector for some time likely will continue as three commission seats are filled, says advertising practices official Richard Cleland.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts